Dihexa is discussed in the research literature as an angiotensin IV analogue with a published chemical name. The original overview of this page asked about cognitive-model hypotheses, stability and formulation documentation, and small-molecule identity. Those topics are handled below with care, because one frequently cited 2014 paper has been retracted.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. This page does not provide use instructions and does not repeat retracted claims as evidence.
Published identity
Wells, Azzam, Hiller, and Sardinia identified Dihexa as N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (PNB-0408), also known as Dihexa, and described it as an angiotensin IV analog (Wells et al., 2024). That sentence is used here as a chemical-identity note. Dihexa is a small, modified peptide analogue, not a long linear research peptide of the kind usually filed under a simple amino-acid sequence alone. Identity documentation should therefore use methods suited to that structure, and the name on the quotation should match the report.
Retraction flag — do not treat 2014 JPET findings as evidence
Citation flag. Benoist, Wright, et al., “The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Hippocampal Synaptic Activity,” Journal of Pharmacology and Experimental Therapeutics 2014;351(2):390-402 (doi:10.1124/jpet.114.218735; PMID 25187433), appears in Crossref with the title prefix “RETRACTED.” That article is not cited here as evidence of HGF/c-Met signaling, synaptogenic activity, or procognitive effects. Claims of that kind that depend on the retracted paper, or that were later restated without a separately verified primary source, are not restated on this page as established findings.
Wells and colleagues discuss Dihexa in a Huntington disease review context and allude to earlier work. This draft does not recycle those allusions as verified efficacy claims. A contemporary laboratory file should treat identity, purity, and study design as the documented facts, and should treat mechanism language as unverified unless a non-retracted primary paper is checked independently.
Laboratory documentation
Small-molecule or modified-peptide identity, impurity profiling, and formulation records should be kept with the lot. A purity percentage copied from a generic peptide template is not a complete file. How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, and lot traceability still apply as documentation practices.
Dihexa was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which documents apply in the inquiry. For packing at supply scale, see wholesale peptides.
Formulation, stability, and impurity records still matter for a modified analogue, even when mechanism claims are withheld. The certificate and the quotation should use a name that can be reconciled with the Wells identity note, and they should not rely on a retracted paper to explain why the material was purchased. If a secondary article restates HGF/c-Met or procognitive language that traces to the retracted 2014 JPET article, that language should be treated as unverified until a non-retracted primary source is checked on its own terms.
Selected published literature
- Wells RG, Azzam AF, Hiller AL, Sardinia MF. A brief review of existing therapies and challenges for new disease-modifying treatments for Huntington’s disease. Journal of Huntington’s Disease. 2024;13(1):55-66. doi:10.3233/jhd-231507. PubMed 38489193. Cited for chemical identity (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide / PNB-0408; angiotensin IV analog), not as a use instruction or as a substitute for retracted mechanism claims.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.